Drug Profile
Research programme: nerve-targeted gene therapy - Periphagen
Alternative Names: NC 3; NE 2; NE2 Endomorphin; NG 2; NG2 GAD; NN1 NeurotrophinLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Diamyd Medical
- Developer Diamyd Medical; Periphagen Holdings; University of Michigan
- Class Gene therapies
- Mechanism of Action GABA modulators; Glutamate decarboxylase stimulants; Nerve growth factor stimulants; Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Erectile dysfunction; Glioma; Neuropathic pain; Peripheral nervous system diseases
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (Intradermal, Injection)
- 04 Nov 2017 No recent reports of development identified for research development in Peripheral-nervous-system-diseases(Prevention, Chemotherapy-induced) in USA (Parenteral, Injection)
- 12 Oct 2012 Preclinical development is ongoing for Neuropathic pain in USA